Maravai LifeSciences Appoints Vice President & Chief Financial Officer

SAN DIEGO, June 5, 2017 /PRNewswire/ -- Maravai LifeSciences, Inc., a rapidly growing life sciences reagents business, today announced that Kevin Herde has joined the company as its Vice President and Chief Financial Officer.

Mr. Herde joins Maravai from Sorrento Therapeutics, a publicly-traded biopharmaceutical company, where he was Executive Vice President and Chief Financial Officer. Prior to Sorrento Therapeutics, Mr. Herde served as Vice President of Global Blood Screening and Alliance Management at Hologic, where he managed a multinational business providing molecular diagnostic solutions to improve blood safety in conjunction with the company's strategic partners at Grifols and Novartis, while also leading the company's prostate cancer diagnostics, industrial testing and pharmaceutical services businesses. Mr. Herde was also Vice President, Finance and Corporate Controller for Gen-Probe, the leading independent molecular diagnostics company, prior to its acquisition by Hologic in 2012.

In announcing the appointment, Carl Hull, Maravai's chief executive officer said, "It is a great pleasure to have the opportunity to work with Kevin once again following our years together at Gen-Probe. He is a seasoned operator with over 20 years of experience in a variety of general management and finance roles. We look forward to his leadership in the finance, accounting and information technology functions of our emerging life sciences franchise."

Mr. Herde began his business career as an Audit Manager with KPMG and later served as a Senior Finance Manager for Gateway.  He earned his undergraduate degree in Business Administration at the University of San Diego and is a Certified Public Accountant.

About Maravai LifeSciences
Maravai LifeSciences was formed as a partnership between GTCR, a leading private equity firm, and Carl Hull and Eric Tardif.  Maravai's mission is to build a transformative life sciences products company by acquiring outstanding businesses and accelerating their growth.

Since its founding, Maravai has acquired three companies, each a leader in its market segment.  For 40 years, Vector Laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry and adjacent market segments. TriLink Biotechnologies focuses on manufacturing highly modified nucleic acid products used in life sciences research and as components in other research and diagnostic products.  And, Cygnus Technologies is a leading provider of assays used by biologic therapeutics companies to detect contaminants in the manufacturing process of novel drug compounds.

More information concerning Maravai LifeSciences is available at www.maravai.com.

MEDIA INQUIRIES:
David Weber
[email protected]
(650) 697-2447 ext. 271

SOURCE Maravai LifeSciences

Related Links

http://www.maravai.com